SEC Tracker
Get the app

BioNexus Gene Lab BGLC

BioNexus Gene Lab Q1 FY26: revenue $23K, down 99%; diluted EPS −$0.23

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers BioNexus Gene Lab reported for Q1 FY26, the quarter ended Mar 31, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$23K−99% from $2.1M in Q1 FY2510-Q income statement, on EDGAR
  2. Net income−$544KAgainst −$623K in Q1 FY2510-Q income statement, on EDGAR
  3. Diluted EPS−$0.23Against −$0.04 in Q1 FY2510-Q income statement, on EDGAR
  4. Cash and cash equivalents$1.3M−36% from $2.1M in Q1 FY2510-Q balance sheet, on EDGAR
  5. Cash from operations−$148KAgainst −$824K in Q1 FY2510-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when BioNexus Gene Lab files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Aclarion ACON public float $4M, Jun 30, 2025
  2. Advanced Biomed ADVB public float $3M, Dec 31, 2025
  3. Ludwig Enterprises LUDG public float $10M, Jun 30, 2025
  4. CapForce CFOR public float $12M, Jun 30, 2025
  5. American Shared Hospital Services AMS public float $12M, Jun 30, 2025